Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Lucid Group Inc (LCID) Price & Performance

ADMA Biologics IncTrade
Lucid Group IncTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Lucid Group Inc — how do they compare? ADMA Biologics Inc trades at $9.93 (market cap $2.22B), while Lucid Group Inc trades at $6.39 (market cap $2.64B). The key difference: Lucid Group Inc is the larger of the two by market cap. Which is the better fit depends on your goals.

ADMALCID
Market Cap
$2.22B$2.64B
Sector
HealthConsumer Cyclical
52-Week High
$20.38$24.77
52-Week Low
$7.60$4.62
Enterprise Value
$2.29B$5.54B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.

The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.

Lucid Group Inc

Lucid Group (LCID) trades at $6.61, down 6.11% amid ongoing operational challenges. The stock shows bearish technical signals with negative moving averages and faces fundamental headwinds including consistent quarterly losses, negative profit margins, and substantial cash burn. Recent news highlights an operational reset targeting $1.4 billion in cash improvements and delays to the affordable Cosmos EV launch to 2027.

The outlook remains challenging with deep losses and cash burn overshadowing revenue growth. Analyst consensus is cautious with 67% hold ratings, though the $10.50 price target suggests potential upside. Key risks include execution of turnaround plans, intense EV competition, and funding needs. The stock's direction hinges on successful cost reductions and future product execution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Lucid Group Inc

Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.

Read more on LCID